John Murphy, CEO, The COVID-19 Long-haul Foundation
A mechanistic synthesis of Epstein–Barr virus, persistent SARS-CoV-2, immune dysregulation, and host susceptibility
Abstract
Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is increasingly understood as a biologically heterogeneous postinfectious disorder rather than a single clinical entity. Among the mechanisms under investigation, reactivation of latent viruses—particularly Epstein–Barr virus (EBV)—has attracted substantial attention because SARS-CoV-2 can produce profound and prolonged perturbations of cellular immunity, including altered T-cell function, B-cell responses, inflammatory signalling, and immune surveillance. The resulting immunological environment may permit episodic reactivation of latent herpesviruses and thereby amplify inflammation, tissue injury, autonomic dysfunction, and neurological symptoms.
The evidence, however, does not support the proposition that EBV reactivation is the universal cause of Long COVID. Rather, current data support a multi-hit model in which persistent SARS-CoV-2 antigen, immune dysregulation, latent-virus reactivation, autoimmunity, endothelial dysfunction, metabolic disturbance, and microbiome alterations interact in susceptible hosts.
This review examines the proposed role of viral reactivation within that larger biological network. Particular attention is given to the virology and latency biology of EBV, SARS-CoV-2-induced immune perturbation, host genomics, molecular pathology, neurophysiology, autonomic dysfunction, metabolic consequences, and longitudinal clinical phenotypes. The available evidence supports an important distinction between viral reactivation as a biomarker of immune dysfunction and viral reactivation as a proximate cause of persistent disease. Establishing that distinction will require prospective longitudinal studies incorporating viral-load measurements, tissue sampling, single-cell transcriptomics, epigenomics, host genotyping, and mechanism-directed clinical trials.
Introduction
The conventional understanding of viral infection assumes that the immune system eliminates the pathogen and subsequently returns toward homeostasis.
Long COVID demonstrates that this process can fail.
Patients may experience persistent or recurrent fatigue, post-exertional malaise, cognitive dysfunction, dyspnoea, neuropathic symptoms, sleep disturbance, gastrointestinal abnormalities, dysautonomia, cardiovascular symptoms, pain and sensory disturbance long after the acute SARS-CoV-2 infection has resolved. The syndrome can follow severe disease requiring hospitalisation or an apparently trivial outpatient infection.
The biological heterogeneity is substantial.
Consequently, the central question is no longer simply whether SARS-CoV-2 causes Long COVID, but rather:
What biological processes prevent restoration of homeostasis after SARS-CoV-2 infection?
One candidate process is the reactivation of latent viruses.
Humans harbour a persistent virome, including EBV, cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), varicella-zoster virus and other herpesviruses. These organisms have evolved mechanisms allowing them to remain within the host for decades while being controlled by cellular and humoral immunity.
If SARS-CoV-2 substantially disrupts immune surveillance, latent viruses may periodically escape suppression.
This possibility is particularly compelling for EBV because the virus resides primarily in B lymphocytes and is intimately integrated with the host immune system.
I. EBV Biology Provides a Plausible Mechanistic Substrate
EBV is a double-stranded DNA γ-herpesvirus that establishes lifelong latency after primary infection.
During latency, viral gene expression is restricted and viral genomes persist within host cells.
The virus can transition between:
latent infection → lytic reactivation → viral replication → renewed latency.
The host ordinarily maintains this equilibrium through coordinated CD8+ T-cell, CD4+ T-cell, natural-killer-cell and antibody-mediated surveillance.
Thus, anything that substantially disrupts cellular immune surveillance could theoretically permit viral reactivation.
SARS-CoV-2 infection is capable of producing precisely such immune perturbations.
II. SARS-CoV-2 as an Immunological Perturbation
COVID-19 is not simply a respiratory infection.
SARS-CoV-2 produces systemic changes involving innate immunity, lymphocyte populations, cytokine signalling, endothelial biology and metabolic physiology.
Studies of Long COVID have identified persistent immune abnormalities months after the acute infection, including alterations in T-cell populations and inflammatory pathways. BMJ reviews have accordingly emphasized that Long COVID can involve multiple organ systems and that its mechanisms remain incompletely resolved.
A plausible sequence is therefore:
SARS-CoV-2 infection
↓
immune activation and lymphocyte perturbation
↓
impaired control of latent viruses
↓
EBV/other herpesvirus reactivation
↓
secondary inflammatory signalling
↓
persistent multisystem symptoms.
This model is biologically plausible but remains incompletely demonstrated causally.
III. Evidence Linking EBV Reactivation to Long COVID
Several investigations have reported increased evidence of EBV reactivation among individuals with Long COVID.
Markers include:
- elevated antibodies to EBV early-antigen components;
- altered EBV-specific antibody responses;
- detectable circulating EBV DNA in selected patients;
- and immune signatures compatible with altered control of latent infection.
Reviews of the evidence conclude that EBV reactivation may contribute to symptom persistence in at least a subset of patients, while emphasizing that the available studies remain limited and heterogeneous.
One of the most important early studies reported an association between EBV reactivation markers and Long-COVID symptoms, particularly fatigue and cognitive dysfunction.
The association is intriguing because fatigue and cognitive dysfunction are among the most characteristic manifestations of PASC.
But association alone does not establish causation.
IV. Three Possible Relationships Between EBV and Long COVID
The relationship could take at least three forms.
Model 1: EBV is causal
SARS-CoV-2 disrupts immune control, EBV reactivates, and EBV-mediated inflammation contributes directly to chronic disease.
Model 2: EBV is an amplifier
SARS-CoV-2 initiates Long COVID, while EBV reactivation intensifies an already established pathological process.
Model 3: EBV is a biomarker
Long COVID itself produces immune dysfunction, and EBV reactivation merely indicates the severity of that dysfunction.
These models make different predictions.
A causal model predicts that suppressing EBV replication should improve clinical disease.
An amplifier model predicts partial improvement.
A biomarker model predicts little or no therapeutic benefit from antiviral treatment directed against EBV.
This distinction should be central to future trials.
V. Viral Reactivation and the Immune Exhaustion Problem
One of the most important biological concepts is immune exhaustion.
During prolonged antigen exposure, T cells may remain activated but progressively lose functional capacity.
Characteristics can include:
- diminished cytotoxic function;
- altered cytokine production;
- changes in exhaustion-associated receptors;
- metabolic reprogramming;
- altered differentiation states.
This creates a paradox.
The patient may simultaneously have:
excessive inflammation
and
insufficient antiviral immunity.
Such a state is entirely compatible with persistent or recurrent viral reactivation.
The immune system is active—but ineffective at completely restoring microbiological control.
VI. EBV and B-Cell Biology
EBV’s intimate relationship with B cells makes the B-cell compartment particularly important.
EBV infection alters:
- B-cell activation;
- differentiation;
- antigen presentation;
- cytokine signalling;
- and survival pathways.
A prolonged perturbation of B-cell biology after SARS-CoV-2 infection could therefore have consequences beyond EBV itself.
This may contribute to the broader autoimmune phenotype described in some Long-COVID cohorts.
Persistent antigen exposure can also produce sustained B-cell stimulation, potentially increasing the opportunity for autoreactive clones to emerge.
Thus EBV reactivation and autoimmunity need not be independent mechanisms.
They may reinforce one another.
VII. Molecular Mimicry and Autoimmunity
A second possible pathway involves molecular mimicry.
Viral antigens may resemble host proteins sufficiently to activate cross-reactive immune responses.
SARS-CoV-2 has been associated with diverse autoantibody responses.
If EBV reactivation occurs simultaneously, the antigenic environment becomes considerably more complex.
The immune system is then exposed to:
- SARS-CoV-2 antigens;
- EBV antigens;
- damaged host proteins;
- inflammatory cytokines;
- and tissue-derived danger signals.
This may promote epitope spreading, in which an initially focused immune response broadens to include additional host antigens.
The resulting pathology could persist after the original viral trigger has diminished.
VIII. The Role of Innate Immunity
Long COVID is not solely an adaptive immune disorder.
Innate immune mechanisms may be equally important.
Persistent viral products, damaged cells and microbial products can activate:
- Toll-like receptors;
- RIG-I-like receptors;
- inflammasomes;
- complement;
- macrophages;
- monocytes.
This produces a feed-forward inflammatory system.
A recent synthesis characterizes PASC as potentially involving impaired resolution of innate inflammation, with residual viral antigens, reactivated latent viruses and microbiome-derived products maintaining activation of pattern-recognition and complement pathways.
The implication is important:
viral reactivation may be one input into a larger inflammatory circuit rather than an isolated pathological event.
IX. Endothelial and Microvascular Consequences
Inflammatory activation can profoundly affect the vascular endothelium.
Endothelial dysfunction can produce:
- impaired vasodilation;
- platelet activation;
- leukocyte adhesion;
- altered coagulation;
- abnormal tissue perfusion.
Microvascular abnormalities have been proposed as contributors to Long-COVID exercise intolerance and respiratory symptoms. BMJ discussions have highlighted evidence for impaired gas transfer and possible pulmonary vascular involvement in selected patients.
The physiological consequences may be especially important in:
- skeletal muscle;
- brain;
- myocardium;
- lungs.
A patient can therefore have normal conventional imaging while experiencing abnormal tissue-level physiology.
X. Autonomic Dysfunction
Dysautonomia may provide the bridge between immune pathology and symptoms.
Patients can develop:
- postural tachycardia;
- orthostatic intolerance;
- abnormal blood-pressure responses;
- impaired thermoregulation;
- gastrointestinal dysmotility;
- abnormal sweating;
- exercise intolerance.
Potential mechanisms include:
autoantibodies + endothelial dysfunction + inflammatory injury + peripheral nerve dysfunction → impaired autonomic regulation.
EBV reactivation could theoretically intensify this process through additional immune stimulation.
However, direct evidence that EBV specifically causes autonomic dysfunction in Long COVID remains inadequate.
XI. Neurological Physiology
The neurological phenotype deserves special consideration.
Long COVID can produce:
- brain fog;
- impaired attention;
- memory dysfunction;
- headache;
- dizziness;
- altered smell;
- altered taste;
- neuropathic symptoms;
- sleep abnormalities;
- autonomic dysfunction.
BMJ’s review of COVID-associated neuroinflammation concludes that much of the neurological pathology appears to be immune-mediated, vascular, or a combination of both, rather than widespread direct neuroinvasion.
This distinction is crucial.
The brain can become dysfunctional without being extensively infected.
Potential mechanisms include:
- systemic inflammatory signalling;
- endothelial dysfunction;
- blood–brain-barrier disturbance;
- altered cerebral perfusion;
- microglial activation;
- autonomic dysfunction;
- peripheral immune-mediated nerve injury.
EBV reactivation could contribute indirectly through systemic immune activation.
XII. Genomics: Why Do Some Patients Develop Persistent Disease?
Genomics provides a potential explanation for inter-individual susceptibility.
Relevant biological systems include:
- HLA-mediated antigen presentation;
- interferon signalling;
- innate viral sensing;
- B-cell biology;
- T-cell regulation;
- complement;
- cytokine signalling;
- mitochondrial metabolism.
A particularly interesting question is whether genetic variation influences the ability to maintain EBV latency after SARS-CoV-2 infection.
Recent population-scale genomic research demonstrates that persistent EBV DNA is influenced by host genetic factors involving immune regulation, B-cell biology, antigen presentation and HLA class II pathways.
This establishes a broader principle:
persistent viral states can have measurable host-genetic determinants.
Whether equivalent genetic determinants specifically predispose to EBV reactivation-associated Long COVID remains to be established.
XIII. Epigenetics and Long-Term Immune Memory
Genetics alone cannot explain the duration of Long COVID.
Epigenetic mechanisms may be equally important.
An acute infection can alter:
- DNA methylation;
- histone modification;
- chromatin accessibility;
- transcription-factor activity.
These changes can persist after the initial inflammatory stimulus has disappeared.
The consequence is potentially a form of pathological immune memory.
A cell that has been reprogrammed during acute infection may respond abnormally to subsequent stimuli.
This provides a possible explanation for why some patients develop recurrent exacerbations long after the acute viral illness.
XIV. Mitochondrial Physiology
Energy metabolism represents another convergence point.
Persistent inflammation can alter mitochondrial function through:
- oxidative stress;
- impaired electron transport;
- altered substrate utilisation;
- abnormal calcium signalling;
- reactive oxygen species generation.
A recent molecular review describes interactions among chronic inflammation, oxidative and nitrosative stress, calcium dysregulation, mitochondrial dysfunction and altered cellular stress responses in Long COVID.
The clinical consequence may be impaired capacity to generate ATP efficiently during exertion.
This could contribute to:
fatigue → exertion → metabolic stress → delayed worsening.
That model is particularly relevant to post-exertional malaise.
XV. The Gastrointestinal Reservoir
The gastrointestinal tract may be especially important because it contains both:
- extensive immune tissue; and
- a large microbial ecosystem.
Persistent SARS-CoV-2 material has been detected in gastrointestinal tissues in some studies.
Consequences could include:
- altered epithelial integrity;
- intestinal permeability;
- microbiome dysbiosis;
- mucosal immune activation.
Microbial products entering the circulation could then further stimulate innate immunity.
Thus:
intestinal viral persistence → mucosal injury → dysbiosis → microbial products → systemic inflammation
is a plausible biological circuit.
XVI. A Unified Viral-Reactivation Model
The available evidence supports the following model:
Acute SARS-CoV-2 infection
↓
Immune and tissue perturbation
↓
impaired cellular immune surveillance
↓
reactivation of EBV and/or other latent viruses
↓
secondary antigenic stimulation
↓
innate immune activation
↓
complement/endothelial activation
↓
metabolic and autonomic dysfunction
↓
persistent multisystem disease.
This model does not require EBV to be present continuously.
Periodic reactivation could be sufficient to generate intermittent inflammatory bursts.
That possibility may help explain the characteristic relapsing-remitting course experienced by many patients.
XVII. Clinical Course
Long COVID has several recognizable temporal patterns.
Immediate persistent disease
Symptoms continue directly from the acute infection.
Delayed disease
The patient initially improves and subsequently develops symptoms.
Relapsing disease
Periods of improvement alternate with exacerbations.
Progressive multisystem disease
Symptoms accumulate over time, sometimes involving additional organ systems.
The relapsing phenotype is particularly compatible with episodic immune activation or viral reactivation, although it is not diagnostic of either.
XVIII. Clinical Phenotypes Potentially Associated With Viral Reactivation
A hypothetical EBV-associated phenotype might include:
- profound fatigue;
- cognitive dysfunction;
- sleep disturbance;
- post-exertional malaise;
- lymphadenopathy;
- sore throat;
- constitutional symptoms.
But this phenotype should not be regarded as established.
Long COVID remains clinically heterogeneous.
The presence of fatigue or cognitive impairment alone cannot distinguish EBV-mediated disease from:
- dysautonomia;
- mitochondrial dysfunction;
- neuroinflammation;
- endothelial disease;
- persistent SARS-CoV-2;
- or ME/CFS-like physiology.
XIX. Why EBV Testing Is Not Yet a Diagnostic Test for Long COVID
This point is critical.
A positive EBV antibody test does not establish reactivation.
Most adults have latent EBV.
Consequently:
EBV seropositivity ≠ EBV reactivation.
More informative evidence may include:
- EBV DNAemia;
- rising early-antigen antibodies;
- compatible clinical syndrome;
- transcriptional evidence of lytic activation;
- longitudinal viral-load measurements.
Even these findings do not automatically prove that EBV is causing symptoms.
The strongest evidence would demonstrate that elimination of active EBV replication produces clinical remission.
That evidence is currently insufficient.
XX. Implications for Antiviral Therapy
The viral-reactivation hypothesis naturally raises therapeutic possibilities.
For SARS-CoV-2 persistence, investigators have considered direct-acting antivirals.
For EBV, therapeutic strategies are more difficult because latent EBV is not equivalent to an actively replicating virus.
Conventional nucleoside analogues may suppress lytic replication without eliminating the latent reservoir.
Consequently, treatment directed at EBV would have to distinguish:
latency
from
productive replication.
This distinction is fundamental.
XXI. The Causal Experiment
A definitive study would enroll patients shortly after acute SARS-CoV-2 infection and serially measure:
- EBV DNA;
- EBV early-antigen responses;
- EBV transcriptional activity;
- SARS-CoV-2 RNA;
- SARS-CoV-2 antigen;
- T-cell phenotypes;
- B-cell phenotypes;
- cytokines;
- complement;
- autoantibodies;
- metabolomics;
- autonomic physiology.
Patients would then be followed prospectively for development of PASC.
The crucial observation would be whether EBV reactivation:
precedes symptom development.
If it does, causality becomes more plausible.
XXII. Therapeutic Trials Should Be Endotype-Based
A conventional trial enrolling all Long-COVID patients may produce a negative result because the population contains multiple biological diseases.
Instead, patients could be stratified into:
Persistent SARS-CoV-2 phenotype
Evidence of viral antigen or replication.
EBV-reactivation phenotype
Evidence of active EBV biology.
Autoimmune phenotype
Pathogenic autoantibody or immune signatures.
Dysautonomic phenotype
Objective autonomic dysfunction.
Metabolic phenotype
Abnormal exercise physiology or mitochondrial function.
Neurovascular phenotype
Objective evidence of cerebral or peripheral vascular dysfunction.
Such stratification could transform Long-COVID trials.
XXIII. The Most Important Unresolved Question
The fundamental question is not:
Does EBV reactivate after COVID?
The answer appears to be yes in at least some individuals.
The more important question is:
Does EBV reactivation materially cause or perpetuate the symptoms of Long COVID?
That question remains unanswered.
The distinction between reactivation as cause, amplifier, consequence, or biomarker should therefore be maintained throughout the field.
XXIV. Conclusions
Long COVID is best understood as a disorder of failed biological resolution following SARS-CoV-2 infection.
Persistent SARS-CoV-2 antigen, chronic immune activation, immune exhaustion, autoimmunity, endothelial dysfunction, metabolic abnormalities, autonomic disturbance and microbiome alterations may interact to create persistent disease.
Within this network, reactivation of latent viruses—particularly EBV—provides a compelling additional mechanism.
SARS-CoV-2 can profoundly perturb the immune system. If cellular immune surveillance is impaired, latent EBV may intermittently enter a lytic state, generating additional antigenic stimulation and inflammatory signalling. The resulting process could intensify endothelial dysfunction, autonomic abnormalities, neuroinflammation and metabolic impairment.
But scientific caution is essential.
EBV reactivation is not synonymous with Long COVID, and association is not proof of causation.
The strongest current interpretation is that EBV probably represents an important biological modifier in a subset of patients, rather than the universal explanation for PASC. Reviews and emerging studies support the possibility of EBV and other herpesviruses contributing to persistent inflammation and immune dysregulation, while emphasizing that mechanistic certainty remains incomplete.
The future of Long-COVID medicine therefore lies in moving from the syndrome level to the molecular endotype level.
The relevant clinical question for an individual patient should eventually become:
What biological process is sustaining this patient’s disease?
If the answer is persistent SARS-CoV-2, antiviral therapy may be appropriate.
If it is active EBV reactivation, a fundamentally different intervention may be required.
If it is autoimmune, endothelial, autonomic or metabolic disease, those pathways will require their own targeted approaches.
Long COVID is consequently unlikely to yield to a single therapeutic key.
It will probably require a precision-medicine architecture in which persistent infection, latent-virus reactivation, immune phenotype, host genotype, cellular metabolism and organ physiology are measured together.
That approach offers the strongest prospect of converting an extraordinarily heterogeneous syndrome into biologically defined, testable and treatable diseases.
Numbered References / Footnotes
- Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. BMJ. 2021;374:n1648.
- Brown RL, Benjamin L, Lunn MP, et al. Pathophysiology, diagnosis, and management of neuroinflammation in covid-19. BMJ. 2023;382:e073923.
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21:133–146.
- Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–895.
- Klein J, Wood J, Jaycox JR, et al. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623:139–148.
- Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology. 2022;23:210–216.
- Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763.
- Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. Journal of Clinical Investigation. 2023;133:e163669.
- Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID. Medical Hypotheses. 2023.
- Association and Interaction of Epstein-Barr Virus with SARS-CoV-2 Infection: A Review. 2025.
- Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nature Reviews Immunology. 2023;23:618–634.
- Pretorius E, Venter C, Laubscher GJ, et al. Persistent clotting protein pathology in Long COVID/post-acute sequelae of COVID-19. Cardiovascular Diabetology. 2021;20:172.
- Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758–766.
- Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute COVID-19 sequelae. Clinical Infectious Diseases. 2023;76:e487–e490.
- Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.
- Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine. 2022;28:1461–1467.
- Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine. 2022;28:2398–2405.
- Post-acute sequelae of COVID-19: a disorder of impaired innate immune resolution. Clinical Immunology. 2026. This recent synthesis proposes residual viral antigen, latent-virus reactivation, microbiome-derived products and impaired resolution of innate inflammation as interacting mechanisms.
- Acute COVID-19 and LongCOVID syndrome—molecular implications for therapeutic strategies. 2025. This review describes interactions among persistent viral material, EBV/CMV reactivation, autophagy, oxidative stress, mitochondrial dysfunction, calcium signalling and chronic inflammation.
- The BMJ. Breathing difficulties after covid-19: a guide for primary care. Evidence discussed includes abnormal gas transfer and potential pulmonary vascular/microvascular pathology in Long COVID.